A Phase II Trial of Low-Dose Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies.
Phase of Trial: Phase II
Latest Information Update: 29 Jul 2011
At a glance
- Drugs Arginine butyrate; Ganciclovir; Valganciclovir
- Indications Epstein-Barr virus infections; Lymphoma
- Focus Therapeutic Use
- Sponsors HemaQuest Pharmaceuticals
- 29 Jul 2011 Actual end date (Sept 2009) added as reported by ClinicalTrials.gov.
- 06 Jul 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Jun 2009 New trial record